Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Price Target at $104.45

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have been assigned a consensus recommendation of “Moderate Buy” from the seventeen analysts that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, thirteen have given a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $104.4545.

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Stifel Nicolaus lifted their price objective on Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a report on Monday, December 8th. Morgan Stanley increased their target price on Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Thursday, January 22nd. Finally, Jefferies Financial Group set a $125.00 price target on shares of Structure Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 11th.

Institutional Trading of Structure Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. State of Wyoming bought a new position in Structure Therapeutics in the second quarter valued at about $28,000. EverSource Wealth Advisors LLC boosted its stake in shares of Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after purchasing an additional 901 shares in the last quarter. CWM LLC boosted its stake in shares of Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares in the last quarter. Assetmark Inc. grew its holdings in shares of Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after purchasing an additional 820 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its position in Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock worth $92,000 after purchasing an additional 994 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Stock Performance

NASDAQ:GPCR opened at $69.97 on Friday. Structure Therapeutics has a 52 week low of $13.22 and a 52 week high of $94.90. The firm’s 50-day simple moving average is $75.01 and its 200 day simple moving average is $43.40. The firm has a market cap of $4.25 billion, a price-to-earnings ratio of -57.35 and a beta of -2.07.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.